Orphazyme finds path forward for Niemann-Pick therapy in subgroup data

Orphazyme A/S (CSE:ORPHA) said arimoclomol significantly reduced disease progression in a pair of predefined subgroups in a Phase II/III trial to treat Niemann-Pick disease type C (NPC). The company

Read the full 299 word article

How to gain access

Continue reading with a
two-week free trial.